CompanyGraph
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
300204 · SZSE · China
staidson.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $27.98M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.75BCNY1.60B · vs all stocks (USD)
Revenue (TTM)
187.53MCNY27.98M · vs all stocks (USD)
Profit Margin
-47.94%vs Biotechnology peers
Beta
0.4400xvs all stocks
52-Week Change
-45.33%vs all stocks
Market Capitalization
10.75BCNY1.60B · vs all stocks (USD)
Enterprise Value
9.50BCNY1.42B · vs all stocks (USD)
Forward P/E
25.78xvs Biotechnology peers
Price to Sales (TTM)
57.30xvs Biotechnology peers
Price to Book (MRQ)
12.24xvs Biotechnology peers
Enterprise to Revenue
50.68xvs Biotechnology peers
Enterprise to EBITDA
-153.32xvs Biotechnology peers
Gross Margin
69.84%vs Biotechnology peers
Profit Margin
-47.94%vs Biotechnology peers
Operating Margin
-58.94%vs Biotechnology peers
Return on Assets (TTM)
-4.24%vs Biotechnology peers
Return on Equity (TTM)
-10.62%vs Biotechnology peers
Revenue (TTM)
187.53MCNY27.98M · vs all stocks (USD)
Revenue per Share (TTM)
0.3990CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-26.30%vs Biotechnology peers
Gross Profit (TTM)
140.15MCNY20.91M · vs all stocks (USD)
EBITDA (TTM)
-61.99MCNY-9.25M · vs all stocks (USD)
Net Income (TTM)
-89.90MCNY-13.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-27.23%vs Biotechnology peers
Operating Cash Flow (TTM)
-96.48MCNY-14.40M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-152.93MCNY-22.82M · vs all stocks (USD)
5-Year Average Dividend Yield
2.40%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-14.06MCNYFY2025 · Dec 31, 2025Revenue
220.23MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
50.08MCNYFY2025 · Dec 31, 2025Gross Profit
170.15MCNYFY2025 · Dec 31, 2025Operating Income
-78.41MCNY-11.70M · vs all stocks (USD)
Pre-tax Income
-88.32MCNYFY2025 · Dec 31, 2025Income Tax Expense
-216.59KCNYFY2025 · Dec 31, 2025Net Income
-88.11MCNYFY2025 · Dec 31, 2025EBIT
-79.83MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-54.50MCNYFY2025 · Dec 31, 2025Research & Development
84.94MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
90.81MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
832.24KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.49MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
486.02MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
486.02MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-88.11MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.34MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-147.09MCNYFY2025 · Dec 31, 2025Free Cash Flow
-221.50MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
123.22MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-88.11MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.31MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-61.69MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-74.42MCNYFY2025 · Dec 31, 2025Sale of Investments
21.42MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-52.99MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
80.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-30.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.09MCNYFY2025 · Dec 31, 2025Other Financing Charges
199.72MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
248.64MCNYFY2025 · Dec 31, 2025Shares Outstanding
477.77MSharesUpdated Sep 20, 2026Float Shares
275.05MSharesUpdated Sep 20, 2026% Held by Insiders
37.58%vs all stocks
% Held by Institutions
4.95%vs all stocks
Total Cash (MRQ)
126.16MCNY18.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2640CNYUpdated Sep 20, 2026Total Debt (MRQ)
162.71MCNY24.28M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2057xvs Biotechnology peers
Current Ratio (MRQ)
1.73xvs Biotechnology peers
Book Value per Share (MRQ)
1.62CNYUpdated Sep 20, 2026Total Assets
1.27BCNY188.94M · vs all stocks (USD)
Total Current Assets
252.65MCNYFY2025 · Dec 31, 2025Total Liabilities
459.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.01BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
283.94MCNYFY2025 · Dec 31, 2025Total Current Liabilities
175.55MCNYFY2025 · Dec 31, 2025Cash
123.64MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.74KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
123.64MCNYFY2025 · Dec 31, 2025Accounts Receivable
24.13MCNYFY2025 · Dec 31, 2025Inventory
19.30MCNYFY2025 · Dec 31, 2025Accounts Payable
21.92MCNYFY2025 · Dec 31, 2025Short-term Debt
80.49MCNYFY2025 · Dec 31, 2025Other Current Liabilities
31.86MCNYFY2025 · Dec 31, 2025Long-term Debt
667.20KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
207.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
477.77MCNYFY2025 · Dec 31, 2025Retained Earnings
-496.53MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
806.72MCNY120.38M · vs all stocks (USD)
52-Week Low
18.98CNYUpdated Sep 20, 202652-Week High
42.65CNYUpdated Sep 20, 202652-Week Change
-45.33%vs all stocks
Beta
0.4400xvs all stocks
50-Day MA
22.58CNYUpdated Sep 20, 2026200-Day MA
25.50CNYUpdated Sep 20, 2026Avg 10-Day Volume
11.25MSharesUpdated Sep 20, 2026Avg 30-Day Volume
21.89MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-0.1900CNYUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.48
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.77
Altman Z-Score 13.52: safe zoneNotable
Altman Z-Score: 13.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $27.98M, lower than 95% of all stocks globallySignificant
Revenue (USD): 27,983,716.042Global P5: 35,820,060.775
Market cap is $1.6B, above the global median of $1.2BNotable
Market cap (USD): 1,603,471,152.707Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Yamaichi Electronics Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Ningbo Deye Technology Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Hainan Shennong Seed Industry Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated